TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04634019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financially incentivized knowledge assessments
Description: We will conduct quarterly provider knowledge assessments at selected health facilities and will pay facilities a financial bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These vignettes cover typical patient cases such as malaria, diarrhea and respiratory infections, and assess providers' ability to correctly diagnose and treat hypothetical questions. All medical staff members will be informed hat every 3 month there will be a knowledge assessment based on these vignettes and that the results will determine the total bonus payment made to the facility.
Study: NCT02625467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty
Description: Conventional Penetrating keratoplasty technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pachymetry and Excimer laser assisted lamellar keratoplasty
Description: Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
Study: NCT03271450

Intervention type: DRUG
Intervention: Edoxaban: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Edoxaban: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Edoxaban: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Edoxaban: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Edoxaban: extended treatment (e.g at least 270 days)
Description: 270 days

Intervention type: DRUG
Intervention: Edoxaban: extended treatment (e.g at least 270 days)
Description: 270 days

Intervention type: DRUG
Intervention: Warfarin: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Warfarin: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Warfarin: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Warfarin: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Warfarin: extended treatment (e.g at least 270 days)
Description: 270 days
Study: NCT04092439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Watermelon Juice
Description: 100% Watermelon Juice
Study: NCT01369758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoSure Tissue Removal System
Description: The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
Study: NCT02800681

Intervention type: OTHER
Intervention: Expert panel evaluation
Description: From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'.

Intervention type: OTHER
Intervention: Expert panel evaluation
Description: From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'.
Study: NCT02625467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment posterior to surgery
Description: Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment posterior to surgery
Description: Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
Study: NCT02800681

Intervention type: OTHER
Intervention: Semi-structured psychopathological interviews
Description: Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.

Intervention type: OTHER
Intervention: Semi-structured psychopathological interviews
Description: Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.

Intervention type: OTHER
Intervention: Self-administered rating scales
Description: 1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.

Intervention type: OTHER
Intervention: Self-administered rating scales
Description: 1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.

Intervention type: OTHER
Intervention: Other general interviewer ratings
Description: 1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.

Intervention type: OTHER
Intervention: Other general interviewer ratings
Description: 1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
Study: NCT03765905

Intervention type: DIAGNOSTIC_TEST
Intervention: study
Description: Scube-1 scube-2 scube-3

Intervention type: DIAGNOSTIC_TEST
Intervention: study
Description: Scube-1 scube-2 scube-3
Study: NCT03756844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just Right Challenge Food Club
Description: Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
Study: NCT04410796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 5 IV q 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles
Study: NCT03084081

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 standard therapy
Description: Standard therapy using carbon dioxide for freezing of tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoPen
Description: Provides a means of freezing tissue without the use of gases or liquids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocoagulator
Description: Thermoablation
Study: NCT00158158

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: If unable to quit at quit date, offered usual care to set another quit date.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Reduction
Description: If unable to quit smoking, reduce smoking rate prior to quit date.
Study: NCT03271450

Intervention type: DRUG
Intervention: Warfarin: extended treatment (e.g at least 270 days)
Description: 270 days
Study: NCT02472223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine 5%
Description: One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions.
Study: NCT00978458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Given once daily 5 days a week for 5½ weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given once daily 5 days a week for 5½ weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Given once daily 5 days a week for 5½ weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Given once daily 5 days a week for 5½ weeks
Study: NCT03613740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fucoxanthin
Description: Intervention will be administered 30 minutes before breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention will be administered 30 minutes before breakfast.
Study: NCT04082624

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition condition
Description: Received nutritional information in in-person PowerPoint presentations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective condition
Description: Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental condition
Description: Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation condition
Description: Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
Study: NCT04533061

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens
Study: NCT01210976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: 12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nacl 0.9% coloured with thiamin in same volume and time than levosimendan
Study: NCT03607604

Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.

Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
Study: NCT02363855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1841788(ODM-201)
Description: Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
Study: NCT04453605

Intervention type: OTHER
Intervention: standard treatments
Description: patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
Study: NCT01505244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Before-School Physical Activity
Description: 3 days/week of before-school moderate to vigorous physical activity
Study: NCT02844140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DE-CT's and SE-CT
Description: Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
Study: NCT01209572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calorimetric chamber
Description: Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free living conditions
Description: Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
Study: NCT01899768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345
Description: Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
Study: NCT01306942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT01899768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345
Description: Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345
Description: Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
Study: NCT06071780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: organic product - Virgin Coconut Oil
Description: A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: organic product - Virgin Coconut Oil
Description: A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
Study: NCT01987752

Intervention type: DRUG
Intervention: brimonidine tartrate/timolol maleate Ophthalmic Solution
Description: brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
Study: NCT03236506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet
Description: Drugs will be given to participants to treat hepatitis C infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet
Description: Drugs will be given to participants to treat hepatitis C infection
Study: NCT01306942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT03236506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet
Description: Drugs will be given to participants to treat hepatitis C infection

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological intervention
Description: Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 MG
Description: Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400 MG
Description: Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400 MG
Description: Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
Study: NCT03616470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline, 0.9% Sodium Chloride
Study: NCT01547676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Unclamped partial nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted laparoscopic surgery
Description: Undergo clamped partial nephrectomy
Study: NCT03878043

Intervention type: OTHER
Intervention: Follow-up Care
Description: Follow up care provided upon readmission to patients who were diagnosed with a TSDH upon initial visit.
Study: NCT04021706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anamorelin Hydrochloride
Description: Ghrelin receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is a inert substance
Study: NCT03674307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No screening
Description: No further screening for asymptomatic coronary artery disease after wait-list entry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Screening
Description: Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
Study: NCT01756638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
Study: NCT04268303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing dexmedetomidine (BXCL501)
Description: Sublingual film containing dexmedetomidine (BXCL501)
Study: NCT02472223

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Description: One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
Study: NCT03577483

Intervention type: PROCEDURE
Group type: OTHER
Intervention: voice recordings
Description: A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
Study: NCT04268303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing dexmedetomidine (BXCL501)
Description: Sublingual film containing dexmedetomidine (BXCL501)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Film
Description: Placebo Film for BXCL501
Study: NCT03366974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 5 mg PO, Midazolam 1 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg bid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Description: Grapefruit juice 500 mL